Chemoresistance and chemosensitization in cholangiocarcinoma
- Publication type:
- Journal article
- Metadata:
-
- Autoren
- Jose JG Marin
- Elisa Lozano
- Elisa Herraez
- Maitane Asensio
- Silvia Di Giacomo
- Marta R Romero
- Oscar Briz
- Maria A Serrano
- Thomas Efferth
- Rocio IR Macias
- Autoren-URL
- https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=fis-test-1&SrcAuth=WosAPI&KeyUT=WOS:000428824800027&DestLinkType=FullRecord&DestApp=WOS_CPL
- DOI
- 10.1016/j.bbadis.2017.06.005
- eISSN
- 1879-260X
- Externe Identifier
- Clarivate Analytics Document Solution ID: GB1QH
- PubMed Identifier: 28600147
- ISSN
- 0925-4439
- Ausgabe der Veröffentlichung
- 4
- Zeitschrift
- BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Schlüsselwörter
- Biliary cancer
- Chemotherapy
- Liver cancer
- Multidrug resistance
- Targeted therapies
- Paginierung
- 1444 - 1453
- Datum der Veröffentlichung
- 2018
- Status
- Published
- Titel
- Chemoresistance and chemosensitization in cholangiocarcinoma
- Sub types
- Review
- Ausgabe der Zeitschrift
- 1864
Data source: Web of Science (Lite)
- Other metadata sources:
-
- Autoren
- Jose JG Marin
- Elisa Lozano
- Elisa Herraez
- Maitane Asensio
- Silvia Di Giacomo
- Marta R Romero
- Oscar Briz
- Maria A Serrano
- Thomas Efferth
- Rocio IR Macias
- DOI
- 10.1016/j.bbadis.2017.06.005
- ISSN
- 0925-4439
- Ausgabe der Veröffentlichung
- 4
- Zeitschrift
- Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Sprache
- en
- Paginierung
- 1444 - 1453
- Datum der Veröffentlichung
- 2018
- Status
- Published
- Herausgeber
- Elsevier BV
- Herausgeber URL
- http://dx.doi.org/10.1016/j.bbadis.2017.06.005
- Datum der Datenerfassung
- 2024
- Titel
- Chemoresistance and chemosensitization in cholangiocarcinoma
- Ausgabe der Zeitschrift
- 1864
Data source: Crossref
- Abstract
- One of the main difficulties in the management of patients with advanced cholangiocarcinoma (CCA) is their poor response to available chemotherapy. This is the result of powerful mechanisms of chemoresistance (MOC) of quite diverse nature that usually act synergistically. The problem is often worsened by altered MOC gene expression in response to pharmacological treatment. Since CCA includes a heterogeneous group of cancers their genetic signature coding for MOC genes is also diverse; however, several shared traits have been defined. Some of these characteristics are shared with other types of liver cancer, namely hepatocellular carcinoma and hepatoblastoma. An important goal in modern oncologic pharmacology is to develop novel strategies to overcome CCA chemoresistance either by increasing drug specificity, such as in targeted therapies aimed to inhibit receptors with tyrosine kinase activity, or to increase the amounts of active agents inside CCA cells by enhancing drug uptake or reducing efflux through export pumps. This article is part of a Special Issue entitled: Cholangiocytes in Health and Diseaseedited by Jesus Banales, Marco Marzioni, Nicholas LaRusso and Peter Jansen.
- Addresses
- Experimental Hepatology and Drug Targeting (HEVEFARM), University of Salamanca, IBSAL, Salamanca, Spain; Center for the Study of Liver and Gastrointestinal Diseases (CIBERehd), Carlos III National Institute of Health, Madrid, Spain. Electronic address: jjgmarin@usal.es.
- Autoren
- Jose JG Marin
- Elisa Lozano
- Elisa Herraez
- Maitane Asensio
- Silvia Di Giacomo
- Marta R Romero
- Oscar Briz
- Maria A Serrano
- Thomas Efferth
- Thomas Efferth
- Rocio IR Macias
- DOI
- 10.1016/j.bbadis.2017.06.005
- eISSN
- 1879-260X
- Externe Identifier
- PubMed Identifier: 28600147
- Funding acknowledgements
- CIBERehd: EHD15PI05/2016
- Fundación Samuel Solórzano Barruso, Spain: FS/7-2016
- Fundación Mutua Madrileña, Spain: Call 2015
- Enrico and Enrica Sovena Foundation, Italy:
- Spanish Ministry of Economy, Industry and Competitiveness: SAF2016-75197-R
- Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III, Spain: PI16/00598
- German Research Foundation: DFG/GRK 2015/1
- Open access
- false
- ISSN
- 0925-4439
- Ausgabe der Veröffentlichung
- 4 Pt B
- Zeitschrift
- Biochimica et biophysica acta. Molecular basis of disease
- Schlüsselwörter
- Bile Ducts
- Epithelial Cells
- Humans
- Cholangiocarcinoma
- Bile Duct Neoplasms
- Receptor Protein-Tyrosine Kinases
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Treatment Outcome
- Drug Delivery Systems
- Drug Resistance, Multiple
- Signal Transduction
- Apoptosis
- Cell Survival
- Gene Expression Regulation, Neoplastic
- Drug Resistance, Neoplasm
- Genetic Therapy
- Sprache
- eng
- Medium
- Print-Electronic
- Online publication date
- 2017
- Paginierung
- 1444 - 1453
- Datum der Veröffentlichung
- 2018
- Status
- Published
- Datum der Datenerfassung
- 2017
- Titel
- Chemoresistance and chemosensitization in cholangiocarcinoma.
- Sub types
- Research Support, Non-U.S. Gov't
- Review
- Journal Article
- Ausgabe der Zeitschrift
- 1864
Data source: Europe PubMed Central
- Abstract
- One of the main difficulties in the management of patients with advanced cholangiocarcinoma (CCA) is their poor response to available chemotherapy. This is the result of powerful mechanisms of chemoresistance (MOC) of quite diverse nature that usually act synergistically. The problem is often worsened by altered MOC gene expression in response to pharmacological treatment. Since CCA includes a heterogeneous group of cancers their genetic signature coding for MOC genes is also diverse; however, several shared traits have been defined. Some of these characteristics are shared with other types of liver cancer, namely hepatocellular carcinoma and hepatoblastoma. An important goal in modern oncologic pharmacology is to develop novel strategies to overcome CCA chemoresistance either by increasing drug specificity, such as in targeted therapies aimed to inhibit receptors with tyrosine kinase activity, or to increase the amounts of active agents inside CCA cells by enhancing drug uptake or reducing efflux through export pumps. This article is part of a Special Issue entitled: Cholangiocytes in Health and Diseaseedited by Jesus Banales, Marco Marzioni, Nicholas LaRusso and Peter Jansen.
- Date of acceptance
- 2017
- Autoren
- Jose JG Marin
- Elisa Lozano
- Elisa Herraez
- Maitane Asensio
- Silvia Di Giacomo
- Marta R Romero
- Oscar Briz
- Maria A Serrano
- Thomas Efferth
- Rocio IR Macias
- Autoren-URL
- https://www.ncbi.nlm.nih.gov/pubmed/28600147
- DOI
- 10.1016/j.bbadis.2017.06.005
- ISSN
- 0925-4439
- Ausgabe der Veröffentlichung
- 4 Pt B
- Zeitschrift
- Biochim Biophys Acta Mol Basis Dis
- Schlüsselwörter
- Biliary cancer
- Chemotherapy
- Liver cancer
- Multidrug resistance
- Targeted therapies
- Antineoplastic Agents
- Apoptosis
- Bile Duct Neoplasms
- Bile Ducts
- Cell Survival
- Cholangiocarcinoma
- Drug Delivery Systems
- Drug Resistance, Multiple
- Drug Resistance, Neoplasm
- Epithelial Cells
- Gene Expression Regulation, Neoplastic
- Genetic Therapy
- Humans
- Protein Kinase Inhibitors
- Receptor Protein-Tyrosine Kinases
- Signal Transduction
- Treatment Outcome
- Sprache
- eng
- Country
- Netherlands
- Paginierung
- 1444 - 1453
- PII
- S0925-4439(17)30200-4
- Datum der Veröffentlichung
- 2018
- Status
- Published
- Datum, an dem der Datensatz öffentlich gemacht wurde
- 2018
- Titel
- Chemoresistance and chemosensitization in cholangiocarcinoma.
- Sub types
- Journal Article
- Research Support, Non-U.S. Gov't
- Review
- Ausgabe der Zeitschrift
- 1864
Data source: PubMed
- Beziehungen:
- Property of